Patents Assigned to Genentech
  • Peptidomimetic compounds and antibody-drug conjugates thereof
    Patent number: 9999681
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Grant
    Filed: June 14, 2016
    Date of Patent: June 19, 2018
    Assignee: Genentech, Inc.
    Inventors: John Flygare, Janet Gunzner-Toste, Thomas Pillow, Brian Safina, Vishal Verma, Binqing Wei, Guiling Zhao, Leanna Staben
  • TRICYCLIC PI3K INHIBITOR COMPOUNDS AND METHODS OF USE
    Publication number: 20180162873
    Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
    Type: Application
    Filed: September 7, 2016
    Publication date: June 14, 2018
    Applicant: Genentech, Inc.
    Inventors: Marie-Gabrielle Braun, Keira Garland, Emily Hanan, Hans Purkey, Steven T. Staben, Robert Andrew Heald, Jamie Knight, Calum Macleod, Aijun Lu, Guosheng Wu, Siew Kuen Yeap
  • ASSEMBLY OF BISPECIFIC ANTIBODIES
    Publication number: 20180162955
    Abstract: Described herein are methods for the efficient production of a heteromultimeric protein, such as a bispecific antibody. Heteromultimeric proteins may be capable of specifically binding to more than one target molecule or different epitopes on a single target molecule. The methods modulate parameters to improve assembly of the heteromultimeric proteins at higher yield and efficiency than otherwise possible. Also described are compositions comprising a hinge-containing polypeptide, such as a half-antibody.
    Type: Application
    Filed: October 20, 2017
    Publication date: June 14, 2018
    Applicant: Genentech, Inc.
    Inventors: Glen GIESE, Amy LIM, Josefine PERSSON, Justin SCHEER, Ambrose WILLIAMS
  • TREATMENT WITH ANTI-ErbB2 ANTIBODIES
    Publication number: 20180162951
    Abstract: The present invention concerns the treatment of cancer with anti-ErbB2 antibodies.
    Type: Application
    Filed: January 26, 2018
    Publication date: June 14, 2018
    Applicant: Genentech, Inc.
    Inventor: Robert L. Cohen
  • Pyridazine derivatives as RORc modulators
    Patent number: 9994551
    Abstract: Compounds of formula I: or pharmaceutical salts thereof, wherein R1, R2, R3 and R4 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: November 1, 2017
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, Monique Bodil van Niel, Andrew Cridland, Christopher Hurley, Jonathan Killen, Stuart Ward, Paul Winship
  • Methods for treating progressive multiple sclerosis
    Patent number: 9994642
    Abstract: The present invention concerns methods for treating progressive multiple sclerosis (MS) in a patient, and an article of manufacture with instructions for such use.
    Type: Grant
    Filed: May 16, 2017
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Craig Smith, Peter S. Chin
  • Treatment of pemphigus
    Patent number: 9993550
    Abstract: The present invention concerns treatment of pemphigus with an antibody which binds to CD20.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: June 12, 2018
    Assignees: Genentech, Inc., Biogen Idec Inc.
    Inventors: John G. Curd, Antonio J. Grillo-Lopez
  • Diagnosis and treatments relating to TH2 inhibition
    Patent number: 9995755
    Abstract: Methods of diagnosing and treating disorders related to TH2 inhibition, including but not limited to asthma, are provided. Also provided are methods of selecting or identifying patients for treatment with certain therapeutic agents that are TH2 pathway inhibitors.
    Type: Grant
    Filed: September 9, 2013
    Date of Patent: June 12, 2018
    Assignee: GENENTECH, INC.
    Inventors: Joseph R. Arron, Richard W. Erickson, Michelle Freemer, Meredith Hazen, Guiquan Jia, John G. Matthews, Wendy Putnam, Heleen Scheerens, Yanan Zheng
  • Refolding of recombinant proteins
    Patent number: 9994612
    Abstract: Processes are provided for recovering and purifying refolded recombinant proteins produced in heterologous host cells, which includes the step of refolding the protein in a high pH buffer.
    Type: Grant
    Filed: October 26, 2015
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Shelly Pizarro, Ailen Sanchez, Charles H. Schmelzer
  • Methods and compositions for detecting and treating drug resistant AKT mutant
    Patent number: 9994913
    Abstract: Methods for identifying or diagnosing AKT inhibitor resistant cancers and methods an compositions for treating.
    Type: Grant
    Filed: August 21, 2015
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventor: Kui Lin
  • Coiled coil and/or tether containing protein complexes and uses thereof
    Patent number: 9994646
    Abstract: The invention provides engineered protein complexes constructed using a coiled coil and/or a tether and methods for making, using, and purifying such complexes, such as multispecific antibodies or other multispecific Fc containing complexes.
    Type: Grant
    Filed: June 9, 2015
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Erin H. Christensen, Dan L. Eaton, Andrew C. Vendel, Bernd Wranik
  • Compositions and methods for the diagnosis and treatment of tumor
    Patent number: 9994643
    Abstract: The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: June 12, 2018
    Assignee: Genentech, Inc.
    Inventors: Mark Dennis, Bonnee Rubinfeld, Paul Polakis
  • BICYCLIC AMIDE COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20180153831
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, R2, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds and methods of using the compounds.
    Type: Application
    Filed: November 30, 2017
    Publication date: June 7, 2018
    Applicant: Genentech, Inc.
    Inventors: Snahel Patel, Gregory Hamilton, Guiling Zhao, Huifen Chen
  • Thiazolopyrimidinones and methods of use thereof
    Patent number: 9988400
    Abstract: The present invention relates to certain thiazolopyrimidinone compounds, pharmaceutical compositions comprising such compounds, and methods of treatment using such compounds.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: June 5, 2018
    Assignee: Genentech, Inc.
    Inventors: Yu Jiang, Guosheng Wu, Po-Wai Yuen, Elisia Villemure, Jacob Schwarz, Cuong Ly, Benjamin Sellers, Matthew Volgraf
  • PRODUCTION OF PROTEINS IN GLUTAMINE-FREE CELL CULTURE MEDIA
    Publication number: 20180148510
    Abstract: The present invention relates generally to glutamine-free cell culture media supplemented with asparagine. The invention further concerns the production of recombinant proteins, such as antibodies, in asparagine-supplemented glutamine-free mammalian cell culture.
    Type: Application
    Filed: January 26, 2018
    Publication date: May 31, 2018
    Applicant: Genentech, Inc.
    Inventors: Martin GAWLITZEK, Shun LUO, Christina Teresa BEVILACQUA
  • Pyridazine derivatives as RORc modulators
    Patent number: 9981916
    Abstract: Compounds of the formula I: or a pharmaceutical salt thereof, wherein X, Ar1, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis.
    Type: Grant
    Filed: November 5, 2014
    Date of Patent: May 29, 2018
    Assignee: Genentech, Inc.
    Inventors: Monique Bodil van Niel, Andrew Cridland, Benjamin Fauber, Alberto Gobbi, Christopher Hurley, David Hurst, Jonathan Killen, Robert Maxey, Stuart Ward
  • Anti-JAG1 antibody compositions and methods for treatment of hepatic cancers
    Patent number: 9982058
    Abstract: The present invention relates to methods of treating liver cancer using a Notch signaling inhibitor. Compositions and methods for the treatment of liver cancers are also provided.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: May 29, 2018
    Assignee: Genentech, Inc.
    Inventors: Dorothy French, Erik Huntzicker, Christian W. Siebel
  • Biological markers and methods for predicting response to B-cell antagonists
    Patent number: 9982302
    Abstract: Biological markers that predict patient responsiveness to B-cell antagonists are provided. Also provided are methods of using such biological markers. In addition, methods for identifying patients suffering from an autoimmune disease, e.g., rheumatoid arthritis, who are not likely to respond to B-cell antagonists are provided, as are methods of treating such patients. Methods for selecting therapeutic agents to treat such patients are also provided.
    Type: Grant
    Filed: February 9, 2016
    Date of Patent: May 29, 2018
    Assignee: Genentech, Inc.
    Inventors: Timothy W. Behrens, Kasia Owczarczyk, Michael J. Townsend
  • Tetrahydro-pyrido[3,4-b]indole estrogen receptor modulators and uses thereof
    Patent number: 9980947
    Abstract: Described herein are tetrahydro-pyrido[3,4-b]indol-1-yl compounds with estrogen receptor modulation activity or function having the Formula I structure: and stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such estrogen receptor modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: May 29, 2018
    Assignee: Genentech, Inc.
    Inventors: Sharada Labadie, Jun Liang, Daniel Fred Ortwine, Xiaojing Wang, Jason Zbieg, Birong Zhang, Simon Charles Goodacre, Nicholas Charles Ray, Jun Li
  • Anti-CD79b antibodies and methods of use
    Patent number: 9975949
    Abstract: The invention provides anti-CD79b antibodies and methods of using the same.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: May 22, 2018
    Assignee: Genentech, Inc.
    Inventors: Liping L. Sun, Yvonne Man-Yee Chen, Mark S. Dennis, Allen J. Ebens, Jr., Andrew Polson